Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02746367 · ClinicalTrials.gov registry record
Bipolar Proteomic Assay Validation Study
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Completed
- Registry status
- 261
- Enrollment target
NCT02746367: Completed study, sponsored by Myriad Genetic Laboratories.
NCT02746367 is a clinical trial that has completed, run by Myriad Genetic Laboratories. The registered enrollment target is 261 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02746367 has completed, sponsored by Myriad Genetic Laboratories.
- COMPLETED
- Registry status
- 261 participants
- Enrollment target
Study Summary
The purpose of this study is to validate a set of signatures, based on a panel of proteomic markers, that discriminate BDI, BDII, and MDD in people seeking treatment for a depressive episode.
Primary Outcome
Linear discriminant analysis and multiple logistic regression will be used to create three diagnostic models for the proteomic markers (BDI vs MDD, BDI vs BDII and BDII vs MDD). The patient's model diagnosis will be compared to the patient's clinical diagnoses (based on SCID DSM -5) and the proportion of concordant classifications will be calculated.
Interventions
- OTHER Diagnostic test (LDT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-11-08 |
What the finished NCT02746367 record still lists
NCT02746367 is an observational study that tracks outcomes without assigning an intervention. The registered 261 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Diagnostic test (LDT) is the first listed.
NCT02746367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02746367 about?
NCT02746367 is a clinical study titled "Bipolar Proteomic Assay Validation Study". The purpose of this study is to validate a set of signatures, based on a panel of proteomic markers, that discriminate BDI, BDII, and MDD in people seeking treatment for a depressive episode.
What is the current status of trial NCT02746367?
This trial is currently completed. The enrollment target is 261 participants. The study started on 2016-03. Estimated completion is 2018-11-08.
What interventions are being tested in trial NCT02746367?
The interventions under investigation include: Diagnostic test (LDT) (OTHER).
Who is sponsoring clinical trial NCT02746367?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05124912 · 261 participants · NA
REMASTer: REcurrent Brain Metastases After SRS Trial
- NCT06559891 · 261 participants · NA
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia